uniQure NV (FRA:UQ1)
€ 14.66 0 (0%) Market Cap: 814.57 Mil Enterprise Value: 462.08 Mil PE Ratio: 0 PB Ratio: 15.15 GF Score: 65/100

Uniqure NV Huntingtons Disease Program Update Transcript

Jun 21, 2023 / 12:30PM GMT
Release Date Price: €16.1 (-9.04%)
Operator

Good day, and thank you for standing by. Welcome to the AMT-130 Huntington's Disease Program Update Conference Call. (Operator Instructions) Please be advised today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Maria Cantor. Please go ahead.

Maria E. Cantor
uniQure N.V. - Chief Corporate Affairs Officer

Good morning, and thank you for joining us. This morning, uniQure announced interim data on AMT-130 in patients with Huntington's disease from our ongoing Phase I/II clinical trial in the United States. This update includes safety and tolerability, clinical and functional, biomarker and imaging data on up to 16 patients treated with AMT-130 across 2 dose cohorts. And 10 patients who received an imitation surgical procedure. .

Joining me for this investor event and webcast are Matt Kapusta, our Chief Executive Officer; Dr. Ricardo Dolmetsch, our President of R&D; and Dr. Sarah Tabrizi, professor of Clinical Neurology, Director of the University College London Huntington's Disease Center

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot